Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Freeline Therapeutics Holdings plc FRLN
$3.41
-$0.28 (-8.33%)
На 18:03, 12 мая 2023
+193.26%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
16564214.00000000
-
week52high
1.12
-
week52low
0.24
-
Revenue
0
-
P/E TTM
-187
-
Beta
0.50817300
-
EPS
-1.31000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 апр 2023 г. в 12:00
Описание компании
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 22 авг 2022 г. |
| BTIG | Buy | Buy | 11 авг 2022 г. |
| Morgan Stanley | Equal-Weight | Overweight | 01 февр 2022 г. |
| Redburn Partners | Buy | Neutral | 07 янв 2022 г. |
| BTIG | Buy | 29 ноя 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Freeline to Present at the Stifel Healthcare Conference
GlobeNewsWire
09 ноя 2022 г. в 07:00
LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the Stifel Healthcare Conference being held in New York.
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Zacks Investment Research
09 авг 2022 г. в 09:02
Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.
Freeline Posts Cases Of Lower FIX Expression, Higher Liver Enzymes From Hemophilia Candidate
Benzinga
11 июл 2022 г. в 10:09
Freeline Therapeutics Holdings plc (NASDAQ: FRLN) announced the presentation of safety and initial efficacy data from the first cohort of the Phase 1/2 B-LIEVE trial for FLT180a for hemophilia B. As of the data cut-off of May 23, 2022, a one-time FLT180a dose of 7.7e11 vg/kg.
Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress
GlobeNewsWire
24 июн 2022 г. в 09:32
LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene therapy candidate FLT180a at the International Society on Thrombosis and Haemostasis (ISTH) Congress to be held in London, July 9-13, 2022.